Wait, What's Healthy? FDA Pushes Back Label Rules Again
Published Date: 2/25/2025
Rule
Summary
The FDA is updating what counts as 'healthy' on food labels to help you make smarter snack choices. This change affects food makers who need to follow new rules about nutrient claims. The new rules will start on April 28, 2025, giving companies more time to get ready without extra costs right now.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
New 'Healthy' Label Definition
The FDA is updating what counts as "healthy" on food labels and the rule changes how companies can make nutrient content claims. You may see different "healthy" labels on snack and food packages after the rule takes effect. The change is meant to help you make smarter snack choices.
Compliance Delayed to April 28, 2025
The rule’s effective date is delayed until April 28, 2025, which gives food makers more time to prepare for the new nutrient content claim requirements. The document states this delay gives companies more time to get ready and says there are no extra costs right now.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-03038 — Manufactured Home Construction and Safety Standards; Postponing Effective Date
HUD is pushing back the new safety rules for manufactured homes from March 17, 2025, to September 15, 2025. This delay gives everyone more time to get ready and follows a government-wide pause on new regulations. Home builders and buyers should note the new timeline but won’t see any immediate cost changes yet.
Next: 2025-02974 — West Virginia Underground Injection Control (UIC) Program; Class VI Primacy
West Virginia just got the green light to manage special underground wells that store carbon dioxide safely, helping fight climate change. The state’s environmental team can now issue permits and keep an eye on these wells, while the EPA still watches over wells on Indian lands. This change means faster local decisions and stronger protection for clean water, with no extra costs for the public.